Acura Pharmaceuticals Inc (ACUR) Return on Equity ROE from the fourth quarter 2021 to fourth quarter 2020 and annually, average high and low, overall ranking from Dec 31 2021 to Dec 31 2020 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Acura Pharmaceuticals inc  (NASDAQ: ACUR)

Acura Pharmaceuticals Inc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Acura Pharmaceuticals Inc in the fourth quarter 2021?
Due to the lack of equity, it was not possible to calculate Acura Pharmaceuticals Inc's return on equity (ROE) in its fourth quarter 2021

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Dec 31 2021)
IV. Quarter		 (Sep 30 2021)
III. Quarter		 (Jun 30 2021)
II. Quarter		 (Mar 31 2021)
I. Quarter		 (Dec 31 2020)
IV. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -1 -1 -2 -1 -1
Return On Equity (TTM) - - - - -
ACUR's Total Ranking # # # # #
Equity (TTM) in Millions 0 0 0 -6 -6
Seq. Equity Change 31.85 % -64.66 % - - -
Seq. Net Income Change - - - - -

Back to ACUR Management Effectiveness >> ACUR's 5 Years Annual ROE >> Compare ACUR ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





ACUR Annual Return On Equity (Dec 31 2021)
2021		 (Dec 31 2020)
2020		 (Dec 31 2019)
2019		 (Dec 31 2018)
2018		 (Dec 31 2017)
2017
Total Equity in Millions 0 -6 -5 -4 0
Y / Y Equity Change - - - - -
Net Income in Millions -1 -1 -4 -4 -6
Y / Y Net Income Change - - - - -
Return On Equity -493.82 % - - - -

Back to ACUR Management Effectiveness >> ACUR's 5 Years Annual ROE >> Compare ACUR ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ACUR's' Return on Equity at Yahoo Finance
ACUR's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ACUR's Competitors
Subscribers only: Roe for Acura Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Equity for ACUR's Customers




Companies with similar Return On Equity at Dec 31 2021, within Healthcare Sector ROE
Sinovac Biotech Ltd  156.97 %
Journey Medical Corp  145.12 %
Moderna Inc   140.21 %
Tivity Health Inc   130.89 %
Altamira Therapeutics Ltd   130.39 %
Ironwood Pharmaceuticals inc   116.93 %
Vyne Therapeutics Inc   106.54 %
Galmed Pharmaceuticals Ltd   106.24 %
Idexx Laboratories Inc  102.84 %
Tenet Healthcare Corp  100.51 %
Molecular Templates Inc   96.66 %
Agios Pharmaceuticals Inc   95.73 %
Davita Inc   93.93 %
Maravai Lifesciences Holdings Inc   87.13 %
Biontech Se  86.54 %
Abbvie Inc   83.48 %
Vivos Therapeutics Inc   74.61 %
Cryo cell International Inc   73.81 %
Amgen Inc   72.53 %
Eli Lilly And Company  72.32 %
Biomx Inc  71.20 %
Novo Nordisk A  70.56 %
Innoviva Inc   69.98 %
Retractable Technologies Inc  69.81 %
Dynavax Technologies Corporation  64.86 %
Uniqure N v   64.35 %
Biodelivery Sciences International Inc   63.64 %
Glucotrack Inc   60.05 %
Ovid Therapeutics Inc   59.58 %
Silo Pharma Inc  57.39 %

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.